EP2259800

Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    4.3.2009
  • :
    7.5.2014
  • :
    09716778.7
  • :
    3.3.2029
  • :
    Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.

4.3.2009
7.5.2014
  • :
    Novartis AG
  • :
    Lichtstrasse 35, 4056, Basel, CH
  • :
    GARCIA-ECHEVERRIA, Carlos
  • :
    Basel, CH
  • :
    MAIRA, Sauveur-Michel
  • :
    Habsheim, FR
  • :
    08152326
  • :
    5.3.2008
  • :
    EP
  • :
    WO2009109605
  • :
    4.3.2009
  • :
    A61K 45/06, A61P 35/00, A61K 31/5377